Is AZN stock expected to gain tomorrow?

**AstraZeneca (AZN) is not expected to have the highest earnings growth or intraday gains among companies reporting earnings tomorrow**. Here's the analysis:

1. **Earnings Growth Expectations**: AstraZeneca's earnings are expected to grow, but the growth rate is not among the highest compared to other companies reporting earnings tomorrow. The consensus estimate for AstraZeneca's EPS is $1.34, indicating a quarter-over-quarter growth rate of 11.67%. While this is a positive growth rate, it is not the highest among the companies reporting earnings tomorrow.

2. **Intraday Gain Expectations**: AstraZeneca's intraday gain potential is modest. The stock has a recent trading volume of 3.12 million shares and a percentage change of 0.58% on July 24, 2024. This indicates a positive sentiment, but the gain is not exceptional compared to other companies reporting earnings.

|Ticker|Name|Percentage Change|Date|code|market_code|
|---|---|---|---|---|---|
|AZN.O|Astrazeneca|0.5873436907919709|20240724|AZN|185|

3. **Market Sentiment and Analyst Ratings**: AstraZeneca has a mixed analyst sentiment. The average holding size of AstraZeneca in investors' portfolios is 0.5%, and the sentiment is negative. This suggests that while some investors are positive, others may have concerns.

|Ticker|Name|Inventory|Date|code|market_code|
|---|---|---|---|---|---|
|AZN.O|Astrazeneca|6.22E9|2022 Q2|AZN|185|
|AZN.O|Astrazeneca|5.078E9|2022 Q3|AZN|185|
|AZN.O|Astrazeneca|4.699E9|2022 Q4|AZN|185|
|AZN.O|Astrazeneca|4.967E9|2023 Q1|AZN|185|
|AZN.O|Astrazeneca|5.051E9|2023 Q2|AZN|185|
|AZN.O|Astrazeneca|5.292E9|2023 Q3|AZN|185|
|AZN.O|Astrazeneca|5.424E9|2023 Q4|AZN|185|
|AZN.O|Astrazeneca|5.337E9|2024 Q1|AZN|185|

4. **Recent Performance and Financial Health**: AstraZeneca's recent performance has been positive, with a year-to-date percentage change of 17.55%. The company's financial report period is from 2023 Q4 to 2024 Q2, and its earnings release time is before the market opens on July 25, 2024. This indicates that the stock will be traded ex-dividend from February 22, 2024.

|Ticker|Name|Earnings Release Date|Date|code|market_code|
|---|---|---|---|---|---|
|AZN.O|Astrazeneca|20240725|20231231-20240701|AZN|185|
|AZN.O|Astrazeneca|20240425|20231231-20240701|AZN|185|
|AZN.O|Astrazeneca|20240208|20231231-20240701|AZN|185|

In conclusion, while AstraZeneca is expected to see earnings growth and has a recent positive performance, it is not positioned as the stock with the highest earnings growth or intraday gains among companies reporting earnings tomorrow.